Trisalus Life Sciences Inc. has announced the publication of clinical data from a single-center study evaluating its Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization. This study, published in the Journal of the Endocrine Society, assesses the safety, feasibility, and early efficacy of Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav® Infusion System. The study involved 22 patients with symptomatic thyroid disease, resulting in 100% technical and clinical success and a 73% mean reduction in thyroid gland volume at six months without major complications. These findings mark an expansion of the company's technology applications beyond liver cancers, offering insights into new treatment options for thyroid disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。